SI-BONE, Inc. (SIBN)

After reaching an important support level, SiBone (SIBN) could be a good stock pick from a technical perspective. SIBN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Intech Investment Management LLC cut its stake in shares of SiBone (NASDAQ: SIBN) by 49.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,073 shares of the company's stock after selling 16,535 shares during the period. Intech Investment

AXQ Capital LP acquired a new stake in shares of SiBone (NASDAQ: SIBN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,390 shares of the company's stock, valued at approximately $290,000. Several other institutional investors and

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.

Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation. Profitability This table compares Spectral Diagnostics and SiBone's

The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably.

SI-BONE, Inc. ( SIBN ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Saqib Iqbal - Director of FP&A and Investor Relations Laura Francis - CEO & Director Anshul Maheshwari - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Gracia Mahoney - BofA Securities, Research Division Young Li - Jefferies LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division David Saxon - Needham & Company, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.16 per share a year ago.

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter

Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asset Management & Custody Banks) saw another quarter of better-than-expected flows, driving earnings upside relative to expectations. SI-Bone (SIBN) (Health Care, Health Care Equipment) was weaker despite reporting a marginal beat on revenue and expectations of improved profitability.

SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2025 after market close on Monday, November 10, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NEWTOWN, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at SI-Bone, Inc. (“SI-Bone”).

SI-BONE, Inc. (NASDAQ:SIBN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Laura Francis - CEO & Director Anshul Maheshwari - Chief Financial Officer Presentation Unknown Analyst All right. Good morning.

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Anshul Maheshwari - Chief Financial Officer Laura A. Francis - CEO & Director Saqib Iqbal - Director of FP&A and Investor Relations Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Craig William Bijou - BofA Securities, Research Division David Joshua Saxon - Needham & Company, LLC, Research Division David Louis Turkaly - Citizens JMP Securities, LLC, Research Division Felipe Raul Lamar - Truist Securities, Inc., Research Division Junwoo Park - Cantor Fitzgerald & Co., Research Division Matthew Oliver O'Brien - Piper Sandler & Co., Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good afternoon, and welcome to SI-BONE Second Quarter 2025 Earnings Conference Call.

Si-Bone (SIBN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.